Neurotech Pub

Welcome back to the Season 2 premiere of Neurotech Pub!In this episode, host and Paradromics CEO Matt Angle sits down with fellow Founder/CEOs Carolina Aguilar, Brian Pepin, and Kunal Ghosh to talk shop about building cutting edge neurotech companies from the ground up. We dive deep into business strategies, the neurotech fundraising landscape, emerging therapeutics, and more. We also provide an insider’s view of the intersections of data, pharma, and med devices that are shaping the future of healthcare. Pour yourself a cold one and settle in! Check out full video with transcript here: Check out video and a full episode transcript here. 00:00 | Updates & News >> INBRAIN Neuroelectronics raised a $17M Series A >> Rune Labs raised a $22.8 Million Series A >> Inscopix Launched Cloud-Based Platform for Data Management and Analysis2:15 | Meet the panel and pick up a book1:54 | Jester King Brewery  2:25 | Rune Labs  2:50 | Neurostimulator for deep brain stimulation therapy  3:23 | INBRAIN Neuroelectronics  4:11 | Inscopix  5:24 | Ursula K. Le Guin’s 'The Dispossessed'  6:19 | Yuval Noah Harari’s 'Sapiens: A Brief History of Humankind'  6:32 | Daniel G. Miller’s 'The Tree of Knowledge'  6:40 | Jiddu Krishnamurti’s 'The Book of Life'  7:34 | Barack Obama’s 'A Promised Land,' ‘Dreams from my Father,’ & ‘The Audacity of Hope’  7:56 | Karl Popper’s 'The Open Society and Its Enemies'9:25 | Venture Capital in Neurotech34:44 | Business Strategy in Neurotech40:32 | Tom Oxley, CEO, Synchron  43:58 | Dr. Thomas Insel  44:06 | Mindstrong Mental Health Care  44:35 | Aduhelm controversy  52:25 | Galvani Bio  59:39 | Percept Neurostimulator  1:00:32 | Neuromodulation and the future of treating brain disease  1:07:21 | Software as a Medical Device FDA Guidance1:09:12 | State of Animal Model Systems1:14:28 | α-Synuclein in Parkinson's Disease  1:18:01 | Alto Neuroscience  1:18:36 | Flatiron Foundation  1:18:45 | Gaurdent Health  1:19:03 | Melanoma Trends & Rates1:21:41 | The Pharma-Data-Device Ecosystem 1:21:42 | Frank Fischer, Chairman of Neuropace  1:22:28 | Neurotech Pub Season 1, Episode 9  1:26:35 | Roche acquisition of Flatiron Health & merger with Foundation Medicine   1:27:12 | Companion Diagnostics  1:28:29 | Adhulem and PET imaging  1:29:09 | Resignations at the FDA over Alzheimer’s Drug  1:29:32 | Derek Lowe’s take on the Aducanumab Approval, FDA Committee Votes, Halting the Aducanumab Trials, & The FDA Advisory Committee Briefing Document on Aducanumab  1:31:39 | Donanemab receives breakthrough therapy designation in 2021  1:36:58 | Mapping the Frontal-Vagal Pathway  1:37:09 | The Human Connectome Project  1:40:07 | Teal Organizations and Holacracy  1:41:18 | Society for Neuroscience  1:44:37 | Affymetrix (Thermo Fisher Scientific)  1:44:39 | IlluminaWant more?Follow Paradromics & Neurotech Pub on Twitter  Follow Matt, Brian, Carolina, & Kunal on Twitter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to the Season 1 finale of Neurotech Pub! In this episode, host and Paradromics CEO, Matt Angle, speaks with fellow Neurotech CEOs, Konstantinos Alataris, Frank Fischer, and Marcus Gerhardt. "We cover a lot in this discussion, but one of the big themes is how challenging it can be to raise money, to build neuro devices. This episode was originally recorded last winter, and it was instantly one of my favorite episodes. So like a fine wine, I laid it down until the time was right to share it with friends.Since the episode was recorded, Nesos, Paradromics, and BlackRock all had major funding announcements. Nesos and BlackRock underwent rebranding campaigns, and NeuroPace went public on Nasdaq. This podcast was recorded during a bleak winter, but our optimism proved prescient. The podcast aged well, and now the field is the strongest, best funded, and most exciting that it's ever been. I know you'll enjoy the discussion."- Matt Angle, CEO, ParadromicsCheck out full video with transcript here: https://www.paradromics.com/podcast/neurotech-pub-episode-9-building-and-funding-neurotech-companies 01:08 | Meeting Heros08:02 | Company Origins: NeuroPace, Blackrock Neuro, and Nēsos25:28 | Now vs Then, a Decade of Neurotech Entrepreneurship1:04:50 | Investor Backing in Neurotech1:20:44 | BCI Future Is UnderwayWant more? Follow Paradromics & Neurotech Pub on Twitter  Follow Matt A, and Blackrock Neurotech on Twitter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gyorgy Buzsaki, legendary hippocampal rhythm researcher; Nanthia Suthana, neurosurgeon-bioengineer studying human episodic memory; Dan Rizzuto, brain–machine interface leader and CEO; Nick Halper, electrophysiology entrepreneur. They explore types of memory, how hippocampal circuits bind episodes, timing and rhythms for boosting learning, decoding/reconstructing memories with BCI, and clinical paths toward memory prosthetics.

Ana Maiques, CEO of Neuroelectrics, builds clinical non‑invasive brain stimulation. Anna Wexler, UPenn neuroethicist, studies DIY and consumer brain tech. Stephanie Naufel Thacker, program manager at Facebook Reality Labs, runs neuroethics collaborations. Karen Rommelfanger, Emory neuroethicist, designs societal frameworks. They discuss embedding ethicists in industry, neural data privacy and technical protections, what different modalities can and cannot reveal, and missing voices in policy.

Dima Rinberg, NYU professor studying olfactory coding and bioelectronic noses. Andreas Schaefer, neuroscientist probing olfactory circuits with imaging and computation. Gabriel Lavella, CEO building neural-interface–enabled olfactory detectors. They explore how noses encode odors, dimensionality of odor space, imaging and recording methods, engineered receptors, and real-world applications of portable olfactory BCIs.

Sydney Cash, epileptologist and MGH neurotech researcher; Leigh Hochberg, neurologist leading BrainGate trials; Timothy Brown, philosopher studying agency and BMIs; Amanda Pustilnik, law professor on brain, pain, and policy. They debate what makes neuroethics unique. They cover device versus drug tradeoffs. They dig into data privacy, legal protections, equity of access, coercion risks, and cultural impacts of BCIs.

Carson Stringer, Janelia group leader focused on large-scale neural data and dimensionality reduction. Chethan Pandarinath, professor developing latent dynamical models for neural decoding. Konrad Kording, UPenn professor in computational neuroscience and education. Vikash Gilja, UCSD professor working on neural prostheses and translational neuroengineering. They dive into dimensionality reduction, PCA, noise and reliability, random projections, LFADS, and scaling recordings.

Stuart Cogan, a biomedical engineering professor focused on electrode materials and encapsulation; Thomas Stieglitz, a microtechnology professor working on polyimide neural interfaces; Loren Rieth, an associate professor known for the Utah array; Vanessa Tolosa, a neurotech practitioner expert in flexible polymer devices. They dig into implant packaging, hermetic vs thin-film coatings, feed-throughs and scaling limits, and testing strategies for long-term neural implants.

Frank Willett, a Stanford postdoc who decoded imagined handwriting; Sergey Stavisky, a Stanford postdoc specializing in neural decoding; Vikash Gilja, UCSD neural engineering professor; and Beata Jarosiewicz, senior neuroscientist with BrainGate experience. They explore calibration and closed-loop control, handwriting-based thought-to-text breakthroughs, motor cortex organization beyond the simple homunculus, and tradeoffs between handwriting and speech-decoding approaches.

Philip "Flip" Sabes, neuroscientist and neuroengineer bridging theory and large-scale interfaces. Cindy Chestek, neural engineer focused on implantable electrodes and clinical translation. Tim Harris, instrumentation leader behind Neuropixels and large interdisciplinary projects. They compare labs, startups, and consortia. They debate spike sorting versus population signals. They explore translational hurdles, material longevity, and scalable recording technologies.